Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Novartis AG
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
4
5
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
26May17 20:31
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
23May17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
19May17 12:47
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
18May17 11:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
17May17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
11May17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
04May17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
28Apr17 16:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
26Apr17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
25Apr17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
25Apr17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
24Apr17 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
24Apr17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
21Apr17 18:43
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
19Apr17 22:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
18Apr17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis expands development programs for NASH through clinical collaboration with Allergan
18Apr17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
06Apr17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
03Apr17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
29Mar17 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
29Mar17 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
23Mar17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
22Mar17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22Mar17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21Mar17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
18Mar17 13:45
GNW
0QLR:LON
Novartis AG
Health
208,186m
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
13Mar17 19:08
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 19:08
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
06Mar17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
06Mar17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
28Feb17 12:44
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
24Feb17 12:07
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
23Feb17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
31Jan17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
26Jan17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
26Jan17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
25Jan17 17:31
GNW
0QLR:LON
Novartis AG
Health
208,186m
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
25Jan17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
25Jan17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
06Jan17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
20Dec16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
19Dec16 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16Dec16 12:27
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes
16Dec16 12:23
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
16Dec16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
12Dec16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
12Dec16 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
12Dec16 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
09Dec16 13:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
08Dec16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
07Dec16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
06Dec16 08:45
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
05Dec16 18:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
05Dec16 18:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
05Dec16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
04Dec16 00:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
03Dec16 18:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
29Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
21Nov16 06:20
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
21Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
18Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
16Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
15Nov16 18:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
14Nov16 06:20
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
14Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14Nov16 00:01
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis improves ranking in 2016 Access to Medicine Index
01Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
01Nov16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
31Oct16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
25Oct16 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
25Oct16 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
17Oct16 22:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
09Oct16 07:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
08Oct16 07:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
08Oct16 07:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
03Oct16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
01Oct16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
28Sep16 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
28Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
23Sep16 16:51
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
23Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
21Sep16 22:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
19Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
18Sep16 21:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
17Sep16 10:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
15Sep16 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
15Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
09Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
08Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
03Sep16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
31Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
29Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
25Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
25Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
15Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
03Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
02Aug16 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
19Jul16 06:01
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
19Jul16 06:01
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
«
1
2
3
4
5
»
Date / Time
Source
Company
% Chg
26May17 20:31
GNW
Novartis AG
0.70%
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
23May17 06:15
GNW
Novartis AG
0.70%
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
19May17 12:47
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
18May17 11:05
GNW
Novartis AG
0.70%
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
17May17 06:15
GNW
Novartis AG
0.70%
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
11May17 06:15
GNW
Novartis AG
0.70%
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
04May17 06:15
GNW
Novartis AG
0.70%
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
28Apr17 16:30
GNW
Novartis AG
0.70%
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
26Apr17 06:15
GNW
Novartis AG
0.70%
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
25Apr17 06:00
GNW
Novartis AG
0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
25Apr17 06:00
GNW
Novartis AG
0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
24Apr17 21:30
GNW
Novartis AG
0.70%
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
24Apr17 06:15
GNW
Novartis AG
0.70%
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
21Apr17 18:43
GNW
Novartis AG
0.70%
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
19Apr17 22:00
GNW
Novartis AG
0.70%
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
18Apr17 06:15
GNW
Novartis AG
0.70%
Novartis expands development programs for NASH through clinical collaboration with Allergan
18Apr17 06:10
GNW
Novartis AG
0.70%
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
06Apr17 06:15
GNW
Novartis AG
0.70%
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
03Apr17 06:15
GNW
Novartis AG
0.70%
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
29Mar17 21:00
GNW
Novartis AG
0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
29Mar17 21:00
GNW
Novartis AG
0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
23Mar17 06:15
GNW
Novartis AG
0.70%
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
22Mar17 06:15
GNW
Novartis AG
0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22Mar17 06:15
GNW
Novartis AG
0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21Mar17 06:15
GNW
Novartis AG
0.70%
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
18Mar17 13:45
GNW
Novartis AG
0.70%
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
13Mar17 19:08
GNW
Novartis AG
0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 19:08
GNW
Novartis AG
0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 06:15
GNW
Novartis AG
0.70%
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
06Mar17 06:15
GNW
Novartis AG
0.70%
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
06Mar17 06:10
GNW
Novartis AG
0.70%
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
28Feb17 12:44
GNW
Novartis AG
0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
24Feb17 12:07
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
23Feb17 06:15
GNW
Novartis AG
0.70%
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
31Jan17 06:15
GNW
Novartis AG
0.70%
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
26Jan17 06:15
GNW
Novartis AG
0.70%
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
26Jan17 06:10
GNW
Novartis AG
0.70%
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
25Jan17 17:31
GNW
Novartis AG
0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
25Jan17 06:00
GNW
Novartis AG
0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
25Jan17 06:00
GNW
Novartis AG
0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
06Jan17 06:15
GNW
Novartis AG
0.70%
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
20Dec16 06:15
GNW
Novartis AG
0.70%
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
19Dec16 21:30
GNW
Novartis AG
0.70%
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16Dec16 12:27
GNW
Novartis AG
0.70%
Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes
16Dec16 12:23
GNW
Novartis AG
0.70%
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
16Dec16 06:15
GNW
Novartis AG
0.70%
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
12Dec16 06:15
GNW
Novartis AG
0.70%
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
12Dec16 06:00
GNW
Novartis AG
0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
12Dec16 06:00
GNW
Novartis AG
0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
09Dec16 13:30
GNW
Novartis AG
0.70%
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
08Dec16 06:15
GNW
Novartis AG
0.70%
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
07Dec16 06:15
GNW
Novartis AG
0.70%
Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
06Dec16 08:45
GNW
Novartis AG
0.70%
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
05Dec16 18:30
GNW
Novartis AG
0.70%
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
05Dec16 18:00
GNW
Novartis AG
0.70%
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
05Dec16 06:15
GNW
Novartis AG
0.70%
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
04Dec16 00:00
GNW
Novartis AG
0.70%
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
03Dec16 18:00
GNW
Novartis AG
0.70%
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
29Nov16 06:15
GNW
Novartis AG
0.70%
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
21Nov16 06:20
GNW
Novartis AG
0.70%
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
21Nov16 06:15
GNW
Novartis AG
0.70%
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
18Nov16 06:15
GNW
Novartis AG
0.70%
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
16Nov16 06:15
GNW
Novartis AG
0.70%
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
15Nov16 18:00
GNW
Novartis AG
0.70%
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
14Nov16 06:20
GNW
Novartis AG
0.70%
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
14Nov16 06:15
GNW
Novartis AG
0.70%
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14Nov16 00:01
GNW
Novartis AG
0.70%
Novartis improves ranking in 2016 Access to Medicine Index
01Nov16 06:15
GNW
Novartis AG
0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
01Nov16 06:15
GNW
Novartis AG
0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
31Oct16 06:15
GNW
Novartis AG
0.70%
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
25Oct16 06:00
GNW
Novartis AG
0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
25Oct16 06:00
GNW
Novartis AG
0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
17Oct16 22:00
GNW
Novartis AG
0.70%
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
09Oct16 07:15
GNW
Novartis AG
0.70%
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
08Oct16 07:30
GNW
Novartis AG
0.70%
Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
08Oct16 07:15
GNW
Novartis AG
0.70%
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
03Oct16 06:15
GNW
Novartis AG
0.70%
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
01Oct16 06:15
GNW
Novartis AG
0.70%
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
28Sep16 21:30
GNW
Novartis AG
0.70%
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
28Sep16 06:15
GNW
Novartis AG
0.70%
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
23Sep16 16:51
GNW
Novartis AG
0.70%
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
23Sep16 06:15
GNW
Novartis AG
0.70%
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
21Sep16 22:00
GNW
Novartis AG
0.70%
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
19Sep16 06:15
GNW
Novartis AG
0.70%
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
18Sep16 21:00
GNW
Novartis AG
0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
17Sep16 10:00
GNW
Novartis AG
0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
15Sep16 21:30
GNW
Novartis AG
0.70%
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
15Sep16 06:15
GNW
Novartis AG
0.70%
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
09Sep16 06:15
GNW
Novartis AG
0.70%
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
08Sep16 06:15
GNW
Novartis AG
0.70%
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
03Sep16 06:15
GNW
Novartis AG
0.70%
Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
31Aug16 06:15
GNW
Novartis AG
0.70%
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
29Aug16 06:15
GNW
Novartis AG
0.70%
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
25Aug16 06:15
GNW
Novartis AG
0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
25Aug16 06:15
GNW
Novartis AG
0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
15Aug16 06:15
GNW
Novartis AG
0.70%
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
03Aug16 06:15
GNW
Novartis AG
0.70%
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
02Aug16 06:15
GNW
Novartis AG
0.70%
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
19Jul16 06:01
GNW
Novartis AG
0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
19Jul16 06:01
GNW
Novartis AG
0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
«
1
2
3
4
5
»
Date / Time
Company
% Chg
26May17 20:31
Novartis AG
0.70%
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
23May17 06:15
Novartis AG
0.70%
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
19May17 12:47
Novartis AG
0.70%
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
18May17 11:05
Novartis AG
0.70%
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
17May17 06:15
Novartis AG
0.70%
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
11May17 06:15
Novartis AG
0.70%
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
04May17 06:15
Novartis AG
0.70%
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
28Apr17 16:30
Novartis AG
0.70%
Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
26Apr17 06:15
Novartis AG
0.70%
Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
25Apr17 06:00
Novartis AG
0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
25Apr17 06:00
Novartis AG
0.70%
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
24Apr17 21:30
Novartis AG
0.70%
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
24Apr17 06:15
Novartis AG
0.70%
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
21Apr17 18:43
Novartis AG
0.70%
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
19Apr17 22:00
Novartis AG
0.70%
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
18Apr17 06:15
Novartis AG
0.70%
Novartis expands development programs for NASH through clinical collaboration with Allergan
18Apr17 06:10
Novartis AG
0.70%
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
06Apr17 06:15
Novartis AG
0.70%
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
03Apr17 06:15
Novartis AG
0.70%
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
29Mar17 21:00
Novartis AG
0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
29Mar17 21:00
Novartis AG
0.70%
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
23Mar17 06:15
Novartis AG
0.70%
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
22Mar17 06:15
Novartis AG
0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22Mar17 06:15
Novartis AG
0.70%
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21Mar17 06:15
Novartis AG
0.70%
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
18Mar17 13:45
Novartis AG
0.70%
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
13Mar17 19:08
Novartis AG
0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 19:08
Novartis AG
0.70%
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
13Mar17 06:15
Novartis AG
0.70%
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
06Mar17 06:15
Novartis AG
0.70%
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
06Mar17 06:10
Novartis AG
0.70%
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
28Feb17 12:44
Novartis AG
0.70%
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
24Feb17 12:07
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
23Feb17 06:15
Novartis AG
0.70%
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
31Jan17 06:15
Novartis AG
0.70%
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
26Jan17 06:15
Novartis AG
0.70%
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
26Jan17 06:10
Novartis AG
0.70%
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
25Jan17 17:31
Novartis AG
0.70%
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
25Jan17 06:00
Novartis AG
0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
25Jan17 06:00
Novartis AG
0.70%
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
06Jan17 06:15
Novartis AG
0.70%
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
20Dec16 06:15
Novartis AG
0.70%
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
19Dec16 21:30
Novartis AG
0.70%
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
16Dec16 12:27
Novartis AG
0.70%
Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes
16Dec16 12:23
Novartis AG
0.70%
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
16Dec16 06:15
Novartis AG
0.70%
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
12Dec16 06:15
Novartis AG
0.70%
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
12Dec16 06:00
Novartis AG
0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
12Dec16 06:00
Novartis AG
0.70%
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
09Dec16 13:30
Novartis AG
0.70%
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
08Dec16 06:15
Novartis AG
0.70%
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
07Dec16 06:15
Novartis AG
0.70%
Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
06Dec16 08:45
Novartis AG
0.70%
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
05Dec16 18:30
Novartis AG
0.70%
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
05Dec16 18:00
Novartis AG
0.70%
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
05Dec16 06:15
Novartis AG
0.70%
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
04Dec16 00:00
Novartis AG
0.70%
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
03Dec16 18:00
Novartis AG
0.70%
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
29Nov16 06:15
Novartis AG
0.70%
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
21Nov16 06:20
Novartis AG
0.70%
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
21Nov16 06:15
Novartis AG
0.70%
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
18Nov16 06:15
Novartis AG
0.70%
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
16Nov16 06:15
Novartis AG
0.70%
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
15Nov16 18:00
Novartis AG
0.70%
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
14Nov16 06:20
Novartis AG
0.70%
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
14Nov16 06:15
Novartis AG
0.70%
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14Nov16 00:01
Novartis AG
0.70%
Novartis improves ranking in 2016 Access to Medicine Index
01Nov16 06:15
Novartis AG
0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
01Nov16 06:15
Novartis AG
0.70%
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
31Oct16 06:15
Novartis AG
0.70%
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
25Oct16 06:00
Novartis AG
0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
25Oct16 06:00
Novartis AG
0.70%
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
17Oct16 22:00
Novartis AG
0.70%
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
09Oct16 07:15
Novartis AG
0.70%
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
08Oct16 07:30
Novartis AG
0.70%
Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
08Oct16 07:15
Novartis AG
0.70%
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
03Oct16 06:15
Novartis AG
0.70%
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
01Oct16 06:15
Novartis AG
0.70%
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
28Sep16 21:30
Novartis AG
0.70%
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
28Sep16 06:15
Novartis AG
0.70%
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
23Sep16 16:51
Novartis AG
0.70%
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
23Sep16 06:15
Novartis AG
0.70%
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients
21Sep16 22:00
Novartis AG
0.70%
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
19Sep16 06:15
Novartis AG
0.70%
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
18Sep16 21:00
Novartis AG
0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
17Sep16 10:00
Novartis AG
0.70%
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
15Sep16 21:30
Novartis AG
0.70%
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
15Sep16 06:15
Novartis AG
0.70%
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
09Sep16 06:15
Novartis AG
0.70%
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
08Sep16 06:15
Novartis AG
0.70%
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
03Sep16 06:15
Novartis AG
0.70%
Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups
31Aug16 06:15
Novartis AG
0.70%
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
29Aug16 06:15
Novartis AG
0.70%
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
25Aug16 06:15
Novartis AG
0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
25Aug16 06:15
Novartis AG
0.70%
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
15Aug16 06:15
Novartis AG
0.70%
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
03Aug16 06:15
Novartis AG
0.70%
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
02Aug16 06:15
Novartis AG
0.70%
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
19Jul16 06:01
Novartis AG
0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
19Jul16 06:01
Novartis AG
0.70%
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
«
1
2
3
4
5
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: